
Opinion|Videos|January 29, 2025
Balancing Treatment Benefits and Toxicity: Managing Quality of Life in EGFR+ NSCLC Patients
Key opinion leaders examine approaches to managing skin-related side effects, such as rash, in patients on EGFR inhibitors, highlighting strategies to address quality-of-life impacts while maintaining the benefits of treatment.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What has been your experience in managing skin-related side effects, such as rash, in patients on EGFR inhibitors?
- How do you address the impact of skin toxicity on quality of life versus the benefit of continuing treatment?
Advertisement
Related to this article

As bispecifics and cell therapies move outpatient, Kate Kennedy, MSN, APRN, says nurses and APPs should focus on education and atypical infections.

A 3-minute video and quick-reference list of October's 7 FDA cancer approvals, with the biomarker and monitoring points nurses need for each.

Oral vitamin C did not slow clonal growth in the phase 2 EVITA trial but was linked to longer survival.

Kathryn Shady, PhD, RN, OCN, discusses research on emotional dissonance and vicarious trauma among hematology/oncology nurses.

Ellery Palanuk, MSN, RN, CN-BN, explains how navigators rely on multidisciplinary teams and tumor boards as breast cancer treatment evolves.

At EONS 2026, a City of Hope nurse practitioner explains how shifting immunotherapy from infusion to injection can free nurse and chair time.

Oncology nurses play a key role guiding patients about AI breast cancer risk assessment tools, dynamic re-testing, and individualized screening plans.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Daraxonrasib and RAS Inhibition: What Oncology Nurses Need to Know
2
October 2026 FDA Approvals: 7 Cancer Updates for Oncology Nurses
3
Childhood Leukemia Treatment Disrupts Work, Finances for Most Families
4
Education, Infection Vigilance Define Outpatient Bispecific Care
5

